Published in J Natl Cancer Inst on September 15, 2015
RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst (2016) 1.19
Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open (2016) 0.88
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget (2016) 0.88
Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol (2017) 0.77
Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev (2016) 0.76
Targeted therapies: What have we learned from SHIVA? Nat Rev Clin Oncol (2016) 0.76
Confronting the Care Delivery Challenges Arising from Precision Medicine. Front Oncol (2016) 0.75
Molecular predictive markers in tumors of the gastrointestinal tract. World J Gastrointest Oncol (2016) 0.75
An appraisal of drug development timelines in the Era of precision oncology. Oncotarget (2016) 0.75
Response. J Natl Cancer Inst (2016) 0.75
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. PLoS One (2016) 0.75
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia (2016) 0.75
Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol (2017) 0.75
Debunking the Delusion That Precision Oncology Is an Illusion. Oncologist (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Reporting results of cancer treatment. Cancer (1981) 28.83
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Targeted cancer therapy. Nature (2004) 7.81
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34
Translation of the Philadelphia chromosome into therapy for CML. Blood (2008) 4.74
First FDA authorization for next-generation sequencer. N Engl J Med (2013) 3.70
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med (2013) 2.38
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care (2005) 1.63
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol (2014) 1.53
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
How to obtain the P value from a confidence interval. BMJ (2011) 1.34
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy. Mol Cancer Ther (2012) 1.10
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res (2013) 1.06
Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial. J Clin Oncol (2009) 0.99
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009. Clin Cancer Res (2012) 0.98
New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res (2014) 0.90
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol (2013) 0.85
Hairy cell leukemia: Update on molecular profiling and therapeutic advances. Blood Rev (2014) 0.84